PharmTech AI Pulse Check episode 2 covers AI data governance, API-gated journals, watermarking limits, and why attribution beats detection in GxP.
News|Articles|October 3, 2013
Malvern Instruments Acquires NanoSight
Author(s)Pharmaceutical Technology Editors
Malvern Instruments has acquired NanoSight, the UK-based nanoparticle characterization company.
Advertisement
Malvern Instruments, a provider of instrumentation for materials and biophysical characterization, has acquired nanoparticle characterization company
NanoSight has developed and commercialized Nanoparticle Tracking Analysis (NTA). The company’s instrumentation and software enable multi-parameter analysis and characterization of many different types of nanoscale particles. Nanosight’s ability to analyze particle size, concentration, zeta potential, and aggregation, closely aligns with Malvern’s Zetasizer range, extending Malvern’s solutions for those working at the nanoscale.
NanoSight will continue to operate from its current facilities in Amesbury, Wiltshire, UK, under the existing management team.
Source:
Advertisement
Related to this article
The FDA opened an expedited IND pilot, tightened scrutiny of foreign trial data, and finalized a rule recognizing non-animal testing methods. In Europe, the EMA advanced pharmaceutical legislation reform, restricted 2 legacy products, and opened an injectable-iron safety review.
Novartis licenses Abogen's mRNA-encoded T-cell engager for autoimmune disease, raising scale-up questions for mRNA-lipid nanoparticle manufacturing.
Pharma manufacturing spent 90 years learning that producing correct outputs isn't the same as catching your own errors. AI has only learned the first.
Ron Scarboro, Azurity Pharmaceuticals, explains why real-world usability belongs at product definition and how post-launch feedback should guide drug formulation.
Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.
Gene manufacturing platforms, patient-centric formulations, contract services, packaging innovations, and sterile filling lines are in the spotlight at CPHI Milan 2026.
Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.
Advertisement
Advertisement